Received Jul 25, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV4 | HPV (GARDASIL) | MERCK & CO. INC. | 1 | — | OT |
| HPV4 | HPV (GARDASIL) | MERCK & CO. INC. | 2 | — | OT |
| HPV4 | HPV (GARDASIL) | MERCK & CO. INC. | 3 | — | OT |
neurological injuries; autonomic injuries; extreme pain; Alopecia totalis/alopecia areata/hair loss/autoimmune injuries,autoimmunne disorder; Information has been received from a lawyer regarding a case in litigation and refers to an adolescent (exact age was not provided) male patient (pt). The pt's concurrent conditions, medical history and concomitant therapies were not provided. Prior to receiving his human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL) injections, the pt had no autoimmune, autonomic, or neurological issues. He was a healthy young man, who played baseball daily and was not being followed for any serious medical conditions. On 28-AUG-2014, at the age of 12 years old, the pt was vaccinated with the first dose of human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL) suspension for injection (exact doses, routes of administration, anatomical locations, lot numbers and expiration date were not reported). On 03-NOV-2014, he received the second dose of human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL) suspension for injection (exact dose, route of administration, anatomical location, lot number and expiration date were not reported) and on 30-MAR-2015 (at the age of 14 years old, conflicting information), the pt was vaccinated with the third dose of human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL) suspension for injection (exact dose, route of administration, anatomical location, lot number and expiration date were not reported). All doses were administered for prophylaxis (reported as "touted as a safe and effective vaccine for preventing cervical cancer"), with the pt's mother consent and the pt's physician (referred to as a doctor) recommendation. On 12-JUN-2015, the pt was seen at acupuncture clinic for hair loss that started approximately two weeks earlier. The pt's mother reported that she first noticed the hair loss after a recent haircut. In June 2015, the pt's parents took him to the university for an evaluation of his hair loss and he was treated with a triamcinolone (KENALOG) injection. The pt's hair loss persisted and his parents brought him back to acupuncture clinic on 29-JUN-2015, 03-JUL-2015, and 14-JUL-2015. As the hair loss persisted, on 15-JUL-2015 (also reported as 15-JUL-2025, conflicting information), the pt was seen by dermatologist for alopecia areata on the scalp and was administered a second round of steroid injections. A third round of injections was performed on 12-AUG-2015. Ultimately, the pt was diagnosed with alopecia totalis on 10-SEP-2015. As a result of his post-human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL) symptoms, the pt was unable to engage in normal activities that a normal young person would enjoy. He faced significant stigmatization due to his hair which has drastically affected his social life. He has also undergone numerous treatments to try and reverse the damage which have caused him extreme pain. Based upon his chronic and severe post-human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL) symptoms, the pt was diagnosed with various medical conditions, including but not limited to alopecia totalis. The pt contended that his human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL) injections caused him to develop serious and debilitating autoimmune, autonomic, and neurological, injuries, including but not limited to alopecia totalis, as well as a constellation of adverse symptoms, complications, injuries, and other adverse events, many of which are alleged herein and all of which were caused by human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL) or otherwise linked to his human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL)-induced autoimmune disorder. The outcome of all events was considered to be not recovered. The reporter considered all events to be related to human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL). The reporter considered all events to be disabling.